Belite Bio (BLTE)
(Delayed Data from NSDQ)
$70.20 USD
-3.05 (-4.16%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $70.38 +0.18 (0.26%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
11/11/2025
Time: -- |
9/2025 | $-0.53 | 1.89% |
Earnings Summary
For their last quarter, Belite Bio (BLTE) reported earnings of -$0.50 per share, missing the Zacks Consensus Estimate of -$0.47 per share. This reflects a negative earnings surprise of 6.38%. Look out for BLTE's next earnings release expected on November 11, 2025. For the next earning release, we expect the company to report earnings of -$0.53 per share, reflecting a year-over-year decrease of 89.29%.
Earnings History
Price & Consensus
Zacks News for BLTE
New Strong Sell Stocks for July 22nd
BLTE: What are Zacks experts saying now?
Zacks Private Portfolio Services
BLTE FAQs
Based on past history, Zacks believes Belite Bio, Inc. Sponsored ADR (BLTE) will report their next quarter earnings on November 11, 2025. For the next earning release, we expect the company to report earnings of -0.53 per share, reflecting a year-over-year increase of -89.29.
Based on past history, Zacks believes Belite Bio, Inc. Sponsored ADR (BLTE) will report their previous quarter earnings %%TIME_OF_DAY_CODE%% on November 11, 2025.
The Zacks Consensus Estimate for Belite Bio, Inc. Sponsored ADR (BLTE) for the quarter ending in September 2025 is $-0.53 a share. We expect Belite Bio, Inc. Sponsored ADR to miss by 1.89%.
In the earnings report for the quarter ending in June 2024, Belite Bio, Inc. Sponsored ADR (BLTE) announced earnings of $-0.31 per share versus the Zacks Consensus Estimate of $-0.28 per share, representing a surprise of 10.71%.